Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis.
|Title||Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis.|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Lundquist LM, Cole SW, Sikes ML|
|Journal||World J Orthop|
|Date Published||2014 Sep 18|
Tofacitinib is the first in a new class of nonbiologic disease-modifying antirheumatic drugs (DMARDs), a targeted, synthetic DMARD, approved for the treatment of rheumatoid arthritis (RA) as monotherapy or in combination with methotrexate or other non-biologic DMARD. Tofacitinib, an orally administered Janus kinase (JAK) inhibitor, decreases T-cell activation, pro-inflammatory cytokine production, and cytokine signaling by inhibiting binding of type I cytokine receptors family and γ-chain cytokines to paired JAK1/JAK3 receptors. The net effect of tofacitinb's mechanism of action is decreased synovial inflammation and structural joint damage in RA patients. To date, six phase 3 trials have been conducted to evaluate the safety and efficacy of tofacitinib under the oral rheumatoid arthritis triaLs (ORAL) series. This review describes the pharmacology of the novel agent, tofacitinib, and details the safety and efficacy data of the ORAL trials.
|Alternate Journal||World J Orthop|
|PubMed Central ID||PMC4133456|